Q2 2026 Vext Science Inc Earnings Call Transcript
Key Points
- Adjusted EBITDA grew for a second consecutive quarter, reaching $3.4 million with a margin improvement to 28% from 23%.
- Gross margin improved significantly to 55% from 36% year-over-year, driven by a higher retail sales mix and improved cultivation yields.
- Cultivation yields in Ohio surpassed 100 grams per plant for the first time, a 68% increase over the past 2.5 years, reducing cost of goods.
- The Arizona repositioning is progressing well, with Central Phoenix traffic in June at its strongest since October 2023, and the Eloy property is classified as held-for-sale with proceeds earmarked for debt reduction.
- The company completed a $17 million financing with Wright-Patt Credit Union, refinancing existing debt, acquiring the Jackson, Ohio facility, and funding Ohio expansion.
- Net working capital improved dramatically from negative $11.7 million at year-end to approximately negative $0.9 million in Q2, excluding the noncash uncertain tax position.
- Ohio market remains a growth engine, with statewide sales up 28% in the first half of the year and the new Fairfield store ramping nicely.
- The company corrected its adjusted EBITDA reconciliation, providing more accurate financial reporting without affecting cash metrics.
- Revenue declined 10% year-over-year to $12.1 million, primarily due to the planned reduction in Arizona wholesale activity.
- Arizona wholesale flower prices hit record lows, making cultivation unprofitable and forcing the wind-down of the Eloy facility.
- The company made a pricing misstep in Ohio, setting retail flower prices too high, which temporarily cost volume and customer traffic.
- The Fairfield store underperformed initial expectations due to indirect traffic flow, requiring additional signage and adjustments.
- Operating cash flow was only $1.2 million, below adjusted EBITDA, due to a deliberate $2 million inventory build and $1 million in assumed payables.
- The uncertain tax position increased to $11.7 million from $8.1 million at year-end, though potential 280E relief could reduce it.
- The company faces ongoing competitive pressures in Ohio as new dispensaries open, potentially impacting per-store sales.
- The Columbus store opening is delayed to Q1 2027, and the company expects to provide more CapEx details in Q3.
Thank you for standing by. This is the conference operator. Welcome to the Vext Science second-quarter 2026 financial results conference call. (Operator Instructions) The conference is being recorded. (Operator Instructions)
I would now like to turn the conference over to Priyam Chakraborty. Please go ahead.
Thanks, operator. Good evening, everyone, and thank you for joining us today. Vext's second-quarter 2026 financial results were released earlier today. The press release, financial statements and MD&A are available on SEDAR+ as well as on the Vext website at vextscience.com. We would like to remind listeners that portions of today's discussion include forward-looking statements and that forward-looking statements are included in today's filings.
There can be no assurance that these forward-looking statements will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results contained therein will materialize. Risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
